JP2000247885A - Eye drops for improving eyestrain - Google Patents

Abstract

(57) [Summary] [Objective] To provide an eye drop having a high effect of improving eyestrain caused by overuse of the eyes and mental strain. [Structure] An eye drop for improving eyestrain, which contains caffeine as an active ingredient.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to an eye drop for improving eye strain.

[0002]

2. Description of the Related Art For recovery from eye strain caused by overuse of eyes and mental strain such as Visual Display Terminal (VDT) work, reading, watching work, observation work, etc., a focusing agent methylstigmine methyl sulfate and vitamin B12 are contained. Eye drops have been used.

[0003] Caffeine has a wakefulness effect and is widely used in oral liquids and the like, and as an ophthalmic solution, it has been studied as a solubilizing agent for drugs, but studies on improvement of eye strain have been made. Absent.

[0004]

SUMMARY OF THE INVENTION An object of the present invention is to provide an eye drop having a high effect of improving eye strain caused by overuse of the eyes and mental strain.

[0005]

Means for Solving the Problems As a result of intensive studies, the present inventors have found that an eye drop containing caffeine as an active ingredient can improve eye strain and completed the present invention. In addition, the present invention has found that an ophthalmic solution obtained by combining caffeine with menthol or taurine is very effective in improving eyestrain, and completed the present invention.

[0006]

DESCRIPTION OF THE PREFERRED EMBODIMENTS In the present invention, the amount of caffeine is 0.01 to 1.0% by weight, preferably 0.1 to 0.5% by weight.
%, More preferably 0.1 to 0.15% by weight.

[0007] Further, eye drops obtained by combining menthol or taurine with caffeine have an extremely high effect of improving eyestrain. The amount of menthol is 0.005 to 0.1% by weight, preferably 0.01 to 0.05% by weight. The amount of taurine is 0.1 to 3.0% by weight, preferably 0.2 to 1.0% by weight. The pH and the osmotic pressure are preferably in a range that does not cause irritation to eyes with eye strain. pH is
It is 5.0-8.0, preferably 6.5-7.5. Osmotic pressure is 250
450450 mOsm, preferably 260 to 360 mOsm.

The eye drops of the present invention are prepared by adding caffeine, caffeine and menthol or taurine, dissolving inorganic salts in an amount to give an osmotic pressure of 250 to 450 mOsm in sterilized purified water, and adding a pH adjuster such as borax. By adjusting the pH to 5.0 to 8.0.

The eye drops of the present invention may contain, if necessary, anti-inflammatory agents (dipotassium glycyrrhizinate, epsilon aminocaproic acid, allantoin, berberine chloride, berberine sulfate, sodium azulene sulfonate, zinc sulfate, zinc lactate, lysozyme chloride) ), Vitamins (vitamin B2, vitamin B6, vitamin B12, panthenol, calcium pantothenate, sodium pantothenate, vitamin A acetate, etc.), amino acids (magnesium / potassium L-aspartate, potassium L-aspartate, L- Magnesium aspartate, sodium chondroitin sulfate, etc., preservatives (benzalkonium chloride, chlorobutanol, etc.), buffers (citric acid, boric acid, etc.), pH regulators (borax, etc.), isotonic agents (sodium chloride, etc.) Etc.), dissolution Auxiliaries (polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monooleate, etc.) and the like can be blended within a range that does not impair the effects of the present invention.

[0010]

Industrial Applicability According to the present invention, it has become possible to provide an eye drop having a high effect of improving eyestrain caused by overuse of eyes and mental strain.

[0011]

The present invention will be described in more detail with reference to the following examples and test examples.

Example 1 100 mg of caffeine, 740 mg of sodium chloride and 80 mg of potassium chloride were dissolved in 90 ml of sterile purified water, and the solution was adjusted to pH with borax.
After adjusting to 7.4, add sterile purified water to make the total volume 100 ml
And eye drops were prepared. As a result of measurement, the osmotic pressure of this eye drop was 286 mOsm.

Example 2 Caffeine (100 mg), menthol (10 mg), sodium chloride (740 mg), and potassium chloride (80 mg) were dissolved in sterilized purified water (90 ml), the pH was adjusted to 7.4 with borax, and sterile purified water was added to make a total volume of 100 ml. An eye drop was prepared. As a result of the measurement, the osmotic pressure of this eye drop was 287 mOsm.

Example 3 100 mg of caffeine, 1000 mg of taurine, 500 mg of sodium chloride and 100 mg of potassium chloride were dissolved in 90 ml of sterilized purified water, the pH was adjusted to 7.4 with borax, and the total volume was adjusted to 100 ml with sterilized purified water. An eye drop was prepared. As a result of measurement, the osmotic pressure of this eye drop was 288 mOsm.

Example 4 Caffeine 100 mg, menthol 10 mg, taurine 1000
mg, 500 mg of sodium chloride, and 100 mg of potassium chloride were dissolved in 90 ml of sterilized purified water, the pH was adjusted to 7.4 with borax, and sterilized purified water was added to make the total amount to 100 ml to prepare eye drops. As a result of measurement, the osmotic pressure of this eye drop was 290 mOs
m.

Example 5 Caffeine 500 mg, menthol 10 mg, taurine 1000
mg, 500 mg of sodium chloride, and 100 mg of potassium chloride were dissolved in 90 ml of sterilized purified water, the pH was adjusted to 7.4 with borax, and sterilized purified water was added to make the total amount to 100 ml to prepare eye drops. As a result of measurement, the osmotic pressure of this eye drop was 303 mOs
m.

Comparative Example 1 750 mg of sodium chloride and 90 mg of potassium chloride were dissolved in 90 ml of sterilized purified water, the pH was adjusted to 7.4 with borax, and sterilized purified water was added to make the total amount to 100 ml to prepare eye drops. As a result of measurement, the osmotic pressure of this eye drop was 286 mOsm.

Test Example 1 The eye drop of Example 1 of the present invention was used as a sample, and the eye drop of Comparative Example 1 was used as a control sample.

For 10 healthy subjects, eye strain was reduced for 1 hour.
It was triggered by VDT work (addition work). Then, for each person, 0.1 ml of each eye drop was applied to both eyes once immediately after the end of VDT work, before inducing fatigue (before VDT work), immediately after the end of 1 hour VDT work, and 5 minutes after instillation. , Eye drops 15
After 30 minutes and 30 minutes, the focus adjusting force was measured by a step response method using a focus adjusting force measuring device (Accommodometer AR3-SV14 type [manufactured by Nidek]). As a result, as shown in FIG.
It was found that the focus control improvement rate (recovery rate of control power) was higher than that of the control sample.

Calculation formula Focus adjustment improvement rate (%) = (focus adjustment time after VDT work-focus adjustment time after instillation) × 100 / (focus adjustment time after VDT work-focus adjustment time before VDT work)

Test Example 2 The eye drop of Example 1 of the present invention was used as a sample, and the eye drop of Comparative Example 1 was used as a control sample.

Eye fatigue was induced by 10-hour VDT work (addition work) for 10 healthy volunteers. Then, for each person, 0.1 ml of ophthalmic solution was applied to both eyes once immediately after the end of VDT work, before inducing fatigue (before VDT work), immediately after 1 hour of VDT work, 5 minutes after instillation, The subjective symptoms of eye strain at 15 and 30 minutes were self-determined with a score of 0 (not at all) to 10 (very tired). As a result, as shown in FIG. 2, the ophthalmic solution of the present invention (Example 1) was found to have a higher subjective symptom improvement rate than the ophthalmic solution of Comparative Example 1.

Formula: Symptom symptom improvement rate (%) = (Subject symptom score after VDT work−Subject symptom score after instillation) × 100 / (Subject symptom score after VDT work−Subject symptom score before VDT work)

[Brief description of the drawings]

FIG. 1 shows the focus adjustment improvement rate (recovery rate of accommodation power) of the eye drops prepared in Example 1 as a sample and Comparative Example 1 as a control sample. The horizontal axis represents time, and the vertical axis represents focus adjustment improvement rate. (%).

FIG. 2 shows the subjective symptom improvement rate of asthenopia of the eye drops of the eye drops prepared in Example 1 as a malaise and Comparative Example 1 as a control sample, wherein the horizontal axis represents time and the vertical axis represents the subjective symptom improvement of asthenopia. Shows the rate (%).

Continuation of the front page (72) Inventor Junko Ouchi 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. (72) Inventor Takanori Odan Ogi 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.

Claims (6)

[Claims] (1) An eye drop for improving eyestrain, comprising caffeine as an active ingredient. 2. A composition containing 0.01 to 1.00% by weight of caffeine,
The eye drop for improving eye fatigue according to claim 1, wherein H is 5.0 to 8.0 and osmotic pressure is 250 to 450 mOsm. 3. The eye drop for improving eyestrain according to claim 1, which comprises menthol or taurine. 4. The ophthalmic solution according to claim 1, which contains 0.005 to 0.10% by weight of menthol. 5. The eye drop for improving eye strain according to claim 1, which contains 0.1 to 3.0% by weight of taurine. 6. An eye drop for improving asthenopia, comprising caffeine as a focus control agent.